Namely, CARD9 is a marker of tumor progression and poor prognosis in hepatocarcinoma (HCC), B cell lymphoma, and clear cell renal carcinoma [40–42] and promotes metastatization activating metastasis-associated macrophages (MAM) [43]. Here, CARD9 is linked to B-cell non-Hodgkin lymphoma.